ProCE Banner Activity

My Take on How SGLT2i Provide Opportunities for Cross-Specialty Collaboration in Patients With T2D and HF

Clinical Thought
Expert faculty discusses why healthcare professionals should be vigilant in assessing for HF in patients with T2D and the evolving use of SGLT2 inhibitors in these patients.

Released: June 22, 2021

Expiration: June 21, 2022

No longer available for credit.

Share

Faculty

Jennifer B. Green

Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Provided by

Provided by the Endocrine Society, in collaboration with Clinical Care Options.
ProCE Banner

Supporters

This activity is supported by an independent educational grant from

Boehringer Ingelheim and Eli Lilly

Faculty Disclosure

Primary Author

Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Jennifer B. Green, MD, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim/Lilly, Hawthorne Effect/Omada, Novo Nordisk, Pfizer, and Sanofi/Lexicon and funds for research support from AstraZeneca, Boehringer Ingelheim/Lilly, Merck, Roche, and Sanofi/Lexicon.